Rainer Will

Head

German Cancer Research Center

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rainer Will is the Head at the German Cancer Research Center in Germany. His research is focused on cancer biology, particularly in the areas of glioblastoma resistance mechanisms, therapeutic vulnerabilities in cancer genetics, and the role of oncogenic signaling in tumor progression. Recent publications include studies on the therapeutic implications of PKC in ER+ breast cancer and the regulatory roles of proteins in cell division and glioma treatment.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (3)

Mael Lever

University Hospital Essen

GERMANY

View details

Nicole Dünker

Prof.

Universität Duisburg-Essen

GERMANY

View details

Maike Anna Busch

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rainer Will

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Autophagy suppression via SRC induction represents a therapeutic vulnerability for BAP1 -mutant cancers

An atlas of RNA-dependent proteins in cell division reveals the riboregulation of mitotic protein-protein interactions

PDCD10 Is a Key Player in TMZ-Resistance and Tumor Cell Regrowth: Insights into Its Underlying Mechanism in Glioblastoma Cells

A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.

NLGN4X TCR transgenic T cells to treat gliomas.

Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets.

EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma.

Plakophilin 1 deficiency in prostatic tumours is correlated with immune cell recruitment and controls the up-regulation of cytokine expression post-transcriptionally.

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

Collaborators (3)

Mael Lever

Nicole Dünker

Maike Anna Busch

Make your next move.